News

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, analyst Judah Frommer from Morgan Stanley raised the firm’s ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is among the best growth stocks to invest in for the next 5 years. The General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), David O.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a Massachusetts-based commercial-stage biopharmaceutical company that discovers and commercializes novel therapeutic compounds for underserved diseases.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a Massachusetts-based commercial-stage biopharmaceutical company that discovers and commercializes novel therapeutic compounds for underserved diseases.
Captrust Financial Advisors purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund ...
Fintel reports that on May 9, 2025, B of A Securities downgraded their outlook for Apellis Pharmaceuticals (NasdaqGS:APLS) from Buy to Neutral. Analyst Price Forecast Suggests 147.77% Upside As of ...
APLS now considers sexually explicit material as any content—written, visual, or audio—that depicts or describes sexual acts, nudity, or related conduct.
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co ...
Fintel reports that on December 17, 2024, Goldman Sachs downgraded their outlook for Apellis Pharmaceuticals (NasdaqGS:APLS) from Buy to Neutral. Analyst Price Forecast Suggests 37.12% Upside As ...
The APLS recently introduced a new rule for categorizing books in a three-tiered system for adults, teens, and children, following complaints about LGBTQ+ themes in books.